Information Provided By:
Fly News Breaks for February 15, 2018
CHE
Feb 15, 2018 | 07:52 EDT
Oppenheimer analyst Michael Wiederhorn raised his price target for Chemed to $275 from $270 after the company reported a Q4 beat and issued "robust" FY2018 guidance. The analyst reiterates an Outperform rating on the shares.